CN1730026A - 延胡索滴丸及其制备方法 - Google Patents
延胡索滴丸及其制备方法 Download PDFInfo
- Publication number
- CN1730026A CN1730026A CN 200510090254 CN200510090254A CN1730026A CN 1730026 A CN1730026 A CN 1730026A CN 200510090254 CN200510090254 CN 200510090254 CN 200510090254 A CN200510090254 A CN 200510090254A CN 1730026 A CN1730026 A CN 1730026A
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- substrate
- drug extract
- ester
- corydalis tuber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000218176 Corydalis Species 0.000 title claims abstract description 42
- 239000006187 pill Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 7
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 131
- 239000002202 Polyethylene glycol Substances 0.000 claims description 128
- 239000003814 drug Substances 0.000 claims description 95
- 239000000758 substrate Substances 0.000 claims description 78
- 150000002148 esters Chemical class 0.000 claims description 75
- 229940079593 drug Drugs 0.000 claims description 71
- 239000000284 extract Substances 0.000 claims description 69
- 229920000136 polysorbate Polymers 0.000 claims description 46
- 229920000858 Cyclodextrin Polymers 0.000 claims description 41
- 239000001116 FEMA 4028 Substances 0.000 claims description 41
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 41
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 41
- 229960004853 betadex Drugs 0.000 claims description 41
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 40
- 229920002472 Starch Polymers 0.000 claims description 40
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 40
- 239000011734 sodium Substances 0.000 claims description 40
- 229910052708 sodium Inorganic materials 0.000 claims description 40
- 235000019698 starch Nutrition 0.000 claims description 40
- 239000008107 starch Substances 0.000 claims description 40
- -1 sorbitol anhydride Chemical class 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 239000004615 ingredient Substances 0.000 claims description 16
- 229930013930 alkaloid Natural products 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000002131 composite material Substances 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000001828 Gelatine Substances 0.000 claims description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 8
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 8
- 229920001983 poloxamer Polymers 0.000 claims description 8
- 229960000502 poloxamer Drugs 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 8
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 8
- 239000008117 stearic acid Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 235000015424 sodium Nutrition 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 2
- 206010061216 Infarction Diseases 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 229940023488 pill Drugs 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 8
- 150000003797 alkaloid derivatives Chemical class 0.000 description 6
- 206010008479 Chest Pain Diseases 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 5
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 5
- 206010000891 acute myocardial infarction Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 4
- BZKUYNBAFQJRDM-UHFFFAOYSA-N aporphine Chemical compound C12=CC=CC=C2CC2N(C)CCC3=CC=CC1=C32 BZKUYNBAFQJRDM-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000000428 dust Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UABBYTGYXLXVNA-FKIZINRSSA-N (13s,13ar)-3,9,10-trimethoxy-13-methyl-6,8,13,13a-tetrahydro-5h-isoquinolino[2,1-b]isoquinolin-2-ol Chemical compound C=1([C@H]2[C@H]3C)C=C(O)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC UABBYTGYXLXVNA-FKIZINRSSA-N 0.000 description 2
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 2
- UICBHOXXGLYZJH-UHFFFAOYSA-N 5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium Chemical compound C1=CC=C2CC[N+]3=CC4=CC=CC=C4C=C3C2=C1 UICBHOXXGLYZJH-UHFFFAOYSA-N 0.000 description 2
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 2
- 235000016551 Potentilla erecta Nutrition 0.000 description 2
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 2
- QCMQEZNBBPGFKQ-UHFFFAOYSA-N Thalisopynine Natural products CN1CCC2=C(OC)C(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 QCMQEZNBBPGFKQ-UHFFFAOYSA-N 0.000 description 2
- 241000372442 Wachendorfia thyrsiflora Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000008622 benzophenanthridines Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 description 2
- 235000015250 liver sausages Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- OBVLTWCOTSTMNM-FKIZINRSSA-N (13s,13ar)-2,9,10-trimethoxy-13-methyl-6,8,13,13a-tetrahydro-5h-isoquinolino[2,1-b]isoquinolin-3-ol Chemical compound C1([C@@H]2C)=CC=C(OC)C(OC)=C1CN1[C@H]2C(C=C(C(=C2)O)OC)=C2CC1 OBVLTWCOTSTMNM-FKIZINRSSA-N 0.000 description 1
- SRADCDOQSQOROE-UHFFFAOYSA-N 3,4,11,12-tetramethoxy-5,8,9,14a-tetrahydroisoquinolino[2,1-c][3]benzazepine-6,14-dione Chemical compound C1CN2C(=O)CC3=C(OC)C(OC)=CC=C3C2C(=O)C2=C1C=C(OC)C(OC)=C2 SRADCDOQSQOROE-UHFFFAOYSA-N 0.000 description 1
- VMPYKUMTWXWJAP-UHFFFAOYSA-N 3H-indole isoquinoline Chemical compound N1=CCC2=C1C=CC=C2.C2=NC=CC1=CC=CC=C21 VMPYKUMTWXWJAP-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- 241000830532 Corydalis yanhusuo Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001640034 Heteropterys Species 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- SRADCDOQSQOROE-FQEVSTJZSA-N Saulatine Natural products O(C)c1c(OC)ccc2[C@H]3C(=O)c4c(cc(OC)c(OC)c4)CCN3C(=O)Cc12 SRADCDOQSQOROE-FQEVSTJZSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OBVLTWCOTSTMNM-UHFFFAOYSA-N Tetrahydrocorybulbin Natural products CC1C2=CC=C(OC)C(OC)=C2CN2C1C(C=C(C(=C1)O)OC)=C1CC2 OBVLTWCOTSTMNM-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
聚乙二醇1000 | 50.0 | 67 | <30 | >10 | + |
聚乙二醇4000 | 50.0 | 82 | <30 | >10 | ++ |
聚乙二醇6000 | 50.0 | 82 | <30 | >10 | ++ |
聚乙二醇10000 | 50.0 | 82 | <30 | >10 | ++ |
聚乙二醇20000 | 50.0 | 81 | <30 | >10 | ++ |
司盘40 | 50.0 | 61 | <30 | >10 | ++ |
硬脂酸聚烃氧40酯 | 50.0 | 80 | <30 | >10 | ++ |
泊洛沙姆 | 50.0 | 80 | <30 | >10 | ++ |
十二烷基硫酸钠 | 50.0 | 63 | <30 | >10 | ++ |
硬脂酸 | 50.0 | 61 | >30 | >10 | +++ |
硬脂酸钠 | 50.0 | 61 | >30 | >10 | +++ |
甘油明胶 | 50.0 | 60 | >30 | >10 | ++ |
虫胶 | 50.0 | 59 | >30 | >10 | + |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
聚乙二醇1000 | 25.0 | 87 | <30 | >10 | ++ |
聚乙二醇4000 | 25.0 | 88 | <30 | <10 | +++ |
聚乙二醇6000 | 25.0 | 89 | <30 | <10 | +++ |
聚乙二醇10000 | 25.0 | 89 | <30 | <10 | +++ |
聚乙二醇20000 | 25.0 | 89 | <30 | <10 | +++ |
司盘40 | 25.0 | 65 | <30 | >10 | +++ |
硬脂酸聚烃氧40酯 | 25.0 | 83 | <30 | >10 | ++ |
泊洛沙姆 | 25.0 | 86 | <30 | <10 | +++ |
十二烷基硫酸钠 | 25.0 | 76 | <30 | >10 | ++ |
硬脂酸 | 25.0 | 76 | >30 | >10 | +++ |
硬脂酸钠 | 25.0 | 73 | >30 | >10 | +++ |
甘油明胶 | 25.0 | 71 | >30 | >10 | ++ |
虫胶 | 25.0 | 71 | >30 | >10 | ++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
聚乙二醇1000 | 10.0 | 85 | <30 | >10 | ++ |
聚乙二醇4000 | 10.0 | 88 | <30 | <10 | +++ |
聚乙二醇6000 | 10.0 | 89 | <30 | <10 | +++ |
聚乙二醇10000 | 10.0 | 89 | <30 | <10 | +++ |
聚乙二醇20000 | 10.0 | 88 | <30 | <10 | +++ |
司盘40 | 10.0 | 66 | <30 | >10 | +++ |
硬脂酸聚烃氧40酯 | 10.0 | 85 | <30 | >10 | ++ |
泊洛沙姆 | 10.0 | 87 | <30 | <10 | +++ |
十二烷基硫酸钠 | 10.0 | 76 | <30 | >10 | +++ |
硬脂酸 | 10.0 | 76 | >30 | >10 | +++ |
硬脂酸钠 | 10.0 | 73 | >30 | >10 | +++ |
甘油明胶 | 10.0 | 73 | >30 | >10 | +++ |
虫胶 | 10.0 | 72 | >30 | >10 | ++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
S40酯∶聚乙二醇=1∶1 | 50.0 | 86 | <30 | <10 | +++ |
S40酯∶聚乙二醇=1∶5 | 50.0 | 87 | <30 | <10 | +++ |
S40酯∶聚乙二醇=1∶10 | 50.0 | 88 | <30 | <10 | +++ |
β环糊精∶聚乙二醇=1∶1 | 50.0 | 82 | <30 | >10 | ++ |
β环糊精∶聚乙二醇=1∶5 | 50.0 | 84 | <30 | >10 | ++ |
β环糊精∶聚乙二醇=1∶10 | 50.0 | 84 | <30 | >10 | ++ |
羧甲基淀粉钠∶聚乙二醇=1∶1 | 50.0 | 83 | <30 | >10 | ++ |
羧甲基淀粉钠∶聚乙二醇=1∶5 | 50.0 | 85 | <30 | >10 | +++ |
羧甲基淀粉钠∶聚乙二醇=1∶10 | 50.0 | 86 | <30 | <10 | +++ |
吐温∶聚乙二醇=1∶1 | 50.0 | 81 | <30 | >10 | ++ |
吐温∶聚乙二醇=1∶5 | 50.0 | 83 | <30 | >10 | ++ |
吐温∶聚乙二醇=1∶10 | 50.0 | 84 | <30 | >10 | ++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
S40酯∶聚乙二醇=1∶1 | 25.0 | 88 | <30 | <10 | +++ |
S40酯∶聚乙二醇=1∶5 | 25.0 | 90 | <30 | <10 | +++ |
S40酯∶聚乙二醇=1∶10 | 25.0 | 90 | <30 | <10 | +++ |
β环糊精∶聚乙二醇=1∶1 | 25.0 | 84 | <30 | >10 | ++ |
β环糊精∶聚乙二醇=1∶5 | 25.0 | 87 | <30 | <10 | ++ |
β环糊精∶聚乙二醇=1∶10 | 25.0 | 88 | <30 | <10 | +++ |
羧甲基淀粉钠∶聚乙二醇=1∶1 | 25.0 | 82 | <30 | >10 | ++ |
羧甲基淀粉钠∶聚乙二醇=1∶5 | 25.0 | 86 | <30 | <10 | +++ |
羧甲基淀粉钠∶聚乙二醇=1∶10 | 25.0 | 86 | >30 | <10 | +++ |
吐温∶聚乙二醇=1∶1 | 25.0 | 80 | >30 | >10 | ++ |
吐温∶聚乙二醇=1∶5 | 25.0 | 82 | >30 | >10 | ++ |
吐温∶聚乙二醇=1∶10 | 25.0 | 81 | >30 | >10 | ++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
S40酯∶聚乙二醇=1∶1 | 10.0 | 89 | <30 | <10 | +++ |
S40酯∶聚乙二醇=1∶5 | 10.0 | 91 | <30 | <10 | +++ |
S40酯∶聚乙二醇=1∶10 | 10.0 | 91 | <30 | <10 | +++ |
β环糊精∶聚乙二醇=1∶1 | 10.0 | 87 | <30 | <10 | ++ |
β环糊精∶聚乙二醇=1∶5 | 10.0 | 90 | <30 | <10 | ++ |
β环糊精∶聚乙二醇=1∶10 | 10.0 | 89 | <30 | <10 | ++ |
羧甲基淀粉钠∶聚乙二醇=1∶1 | 10.0 | 84 | <30 | >10 | ++ |
羧甲基淀粉钠∶聚乙二醇=1∶5 | 10.0 | 87 | <30 | <10 | +++ |
羧甲基淀粉钠∶聚乙二醇=1∶10 | 10.0 | 87 | >30 | <10 | +++ |
吐温∶聚乙二醇=1∶1 | 10.0 | 79 | >30 | >10 | ++ |
吐温∶聚乙二醇=1∶5 | 10.0 | 81 | >30 | >10 | ++ |
吐温∶聚乙二醇=1∶10 | 10.0 | 82 | >30 | >10 | ++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
S40酯∶β环糊精∶聚乙二醇=1∶0.5∶1 | 50.0 | 85 | <30 | >10 | +++ |
S40酯∶β环糊精∶聚乙二醇=1∶3∶5 | 50.0 | 88 | <30 | <10 | +++ |
S40酯∶β环糊精∶聚乙二醇=1∶5∶10 | 50.0 | 88 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶聚乙二醇=1∶0.5∶1 | 50.0 | 89 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶聚乙二醇=1∶3∶5 | 50.0 | 90 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶聚乙二醇=1∶5∶10 | 50.0 | 90 | <30 | <10 | +++ |
S40酯∶吐温∶聚乙二醇=1∶0.5∶1 | 50.0 | 83 | <30 | >10 | ++ |
S40酯∶吐温∶聚乙二醇=1∶3∶5 | 50.0 | 84 | <30 | >10 | ++ |
S40酯∶吐温∶聚乙二醇=1∶5∶10 | 50.0 | 85 | <30 | >10 | ++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
S40酯∶β环糊精∶聚乙二醇=1∶0.5∶1 | 25.0 | 89 | <30 | <10 | +++ |
S40酯∶β环糊精∶聚乙二醇=1∶3∶5 | 25.0 | 90 | <30 | <10 | +++ |
S40酯∶β环糊精∶聚乙二醇=1∶5∶10 | 25.0 | 91 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶聚乙二醇=1∶0.5∶1 | 25.0 | 89 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶聚乙二醇=1∶3∶5 | 25.0 | 90 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶聚乙二醇=1∶5∶10 | 25.0 | 90 | <30 | <10 | +++ |
S40酯∶吐温∶聚乙二醇=1∶0.5∶1 | 25.0 | 85 | <30 | >10 | +++ |
S40酯∶吐温∶聚乙二醇=1∶3∶5 | 25.0 | 87 | <30 | <10 | +++ |
S40酯∶吐温∶聚乙二醇=1∶5∶10 | 25.0 | 86 | <30 | <10 | +++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
S40酯∶β环糊精∶聚乙二醇=1∶0.5∶1 | 10.0 | 89 | <30 | <10 | ++ |
S40酯∶β环糊精∶聚乙二醇=1∶3∶5 | 10.0 | 90 | <30 | <10 | +++ |
S40酯∶β环糊精∶聚乙二醇=1∶5∶10 | 10.0 | 90 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶聚乙二醇=1∶0.5∶1 | 10.0 | 87 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶聚乙二醇=1∶3∶5 | 10.0 | 88 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶聚乙二醇=1∶5∶10 | 10.0 | 90 | <30 | <10 | +++ |
S40酯∶吐温∶聚乙二醇=1∶0.5∶1 | 10.0 | 87 | <30 | <10 | +++ |
S40酯∶吐温∶聚乙二醇=1∶3∶5 | 10.0 | 87 | <30 | <10 | +++ |
S40酯∶吐温∶聚乙二醇=1∶5∶10 | 10.0 | 88 | <30 | <10 | +++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
S40酯∶β环糊精∶吐温∶聚乙二醇=1∶0.5∶0.5∶1 | 50.0 | 83 | <30 | >10 | ++ |
S40酯∶β环糊精∶吐温∶聚乙二醇=1∶3∶3∶5 | 50.0 | 85 | <30 | >10 | ++ |
S40酯∶β环糊精∶吐温∶聚乙二醇=1∶5∶5∶10 | 50.0 | 85 | <30 | >10 | +++ |
S40酯∶羧甲基淀粉钠∶吐温∶聚乙二醇=1∶0.5∶0.5∶1 | 50.0 | 83 | <30 | >10 | ++ |
S40酯∶羧甲基淀粉钠∶吐温∶聚乙二醇=1∶3∶3∶5 | 50.0 | 84 | <30 | >10 | ++ |
S40酯∶羧甲基淀粉钠∶吐温∶聚乙二醇=1∶5∶5∶10 | 50.0 | 85 | <30 | >10 | ++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
S40酯∶β环糊精∶吐温∶聚乙二醇=1∶0.5∶0.5∶1 | 25.0 | 85 | <30 | >10 | ++ |
S40酯∶β环糊精∶吐温∶聚乙二醇=1∶3∶3∶5 | 25.0 | 86 | <30 | <10 | +++ |
S40酯∶β环糊精∶吐温∶聚乙二醇=1∶5∶5∶10 | 25.0 | 86 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶吐温∶聚乙二醇=1∶0.5∶0.5∶1 | 25.0 | 87 | <30 | <10 | ++ |
S40酯∶羧甲基淀粉钠∶吐温∶聚乙二醇=1∶3∶3∶5 | 25.0 | 87 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶吐温∶聚乙二醇=1∶5∶5∶10 | 25.0 | 88 | <30 | <10 | +++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
S40酯∶β环糊精∶吐温∶聚乙二醇=1∶0.5∶0.5∶1 | 10.0 | 88 | <30 | <10 | ++ |
S40酯∶β环糊精∶吐温∶聚乙二醇=1∶3∶3∶5 | 10.0 | 88 | <30 | <10 | +++ |
S40酯∶β环糊精∶吐温∶聚乙二醇=1∶5∶5∶10 | 10.0 | 89 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶吐温∶聚乙二醇=1∶0.5∶0.5∶1 | 10.0 | 86 | <30 | <10 | ++ |
S40酯∶羧甲基淀粉钠∶吐温∶聚乙二醇=1∶3∶3∶5 | 10.0 | 88 | <30 | <10 | +++ |
S40酯∶羧甲基淀粉钠∶吐温∶聚乙二醇=1∶5∶5∶10 | 10.0 | 88 | <30 | <10 | +++ |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100902548A CN100387250C (zh) | 2005-08-12 | 2005-08-12 | 延胡索滴丸 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100902548A CN100387250C (zh) | 2005-08-12 | 2005-08-12 | 延胡索滴丸 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1730026A true CN1730026A (zh) | 2006-02-08 |
CN100387250C CN100387250C (zh) | 2008-05-14 |
Family
ID=35962472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100902548A Expired - Fee Related CN100387250C (zh) | 2005-08-12 | 2005-08-12 | 延胡索滴丸 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100387250C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101077363B (zh) * | 2006-05-22 | 2011-02-09 | 周亚伟 | 一种治疗冠心病心绞痛的中药组合物及其制备方法和用途 |
CN101057890B (zh) * | 2006-04-20 | 2011-07-20 | 周亚伟 | 一种治疗冠心病的中药组合物及其制备方法、制剂和其应用 |
-
2005
- 2005-08-12 CN CNB2005100902548A patent/CN100387250C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101057890B (zh) * | 2006-04-20 | 2011-07-20 | 周亚伟 | 一种治疗冠心病的中药组合物及其制备方法、制剂和其应用 |
CN101077363B (zh) * | 2006-05-22 | 2011-02-09 | 周亚伟 | 一种治疗冠心病心绞痛的中药组合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN100387250C (zh) | 2008-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1660368A (zh) | 一种用于清热解毒的口服滴丸及其制备方法 | |
CN1730030A (zh) | 广金钱草滴丸及其制备方法 | |
CN1301098C (zh) | 毛冬青滴丸及其制备方法 | |
CN1730026A (zh) | 延胡索滴丸及其制备方法 | |
CN1316961C (zh) | 罗汉果滴丸及其制备方法 | |
CN100341487C (zh) | 一种用于消炎的双黄消炎滴丸 | |
CN1634476A (zh) | 麻杏止咳滴丸及其制备方法 | |
CN1730041A (zh) | 头花蓼滴丸及其制备方法 | |
CN1660372A (zh) | 一种具有清热解毒,消炎止痢作用的口服滴丸及其制备方法 | |
CN1297255C (zh) | 黄香滴丸及其制备方法 | |
CN1307985C (zh) | 野牡丹滴丸 | |
CN1301097C (zh) | 一种用于心脑血管疾病的脑心清滴丸及其制备方法 | |
CN1316962C (zh) | 咳喘安滴丸及其制备方法 | |
CN1634452A (zh) | 养阴清肺滴丸 | |
CN1679677A (zh) | 一种具有活血化瘀作用的丹七滴丸及其制备方法 | |
CN1634478A (zh) | 川贝枇杷滴丸及其制备方法 | |
CN1686477A (zh) | 银花芒果滴丸及其制备方法 | |
CN1730085A (zh) | 血尿滴丸及其制备方法 | |
CN1284530C (zh) | 复方羊角滴丸 | |
CN1679541A (zh) | 茶色素滴丸及其制备方法 | |
CN1698831A (zh) | 一种治疗肝炎的茵栀黄滴丸及其制备方法 | |
CN1698783A (zh) | 余甘子滴丸及其制备方法 | |
CN1634473A (zh) | 杏仁止咳滴丸及其制备方法 | |
CN1698782A (zh) | 大黄通便滴丸及其制备方法 | |
CN1686446A (zh) | 贝母花滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 100083 Haidian District, Xueyuan Road, No. 30, A building, room No. 15, room, room 15 Patentee after: COSCI MED-TECH Co.,Ltd. Address before: 100080, room 1410, satellite building, No. 63, Zhichun Road, Beijing, Haidian District Patentee before: COSCI MED-TECH Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20230323 Address after: 8639, Floor 6, Building 3, No. 3, Yongchang North Road, Daxing District, Beijing, 100176 Patentee after: Beijing Kexin Jurun Pharmaceutical Technology Co.,Ltd. Address before: 100083 room 15, 15 / F, block a, Tiangong building, 30 Xueyuan Road, Haidian District, Beijing Patentee before: COSCI MED-TECH Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080514 |
|
CF01 | Termination of patent right due to non-payment of annual fee |